Voyager Therapeutics (VYGR) Promotes Jeff Goater To Chief Financial Officer

Cambridge, Mass., February 2, 2016 (GLOBE NEWSWIRE) – Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former senior vice president of finance and business development, to chief financial officer. In this new role, Mr. Goater will be responsible for overseeing the company's financial strategy and planning, investor and public relations, corporate operations and business development.

"Jeff's exceptional leadership has been and will continue to be instrumental in identifying strategic growth opportunities for Voyager," said Steven Paul, M.D. president and CEO of Voyager Therapeutics. "Since the company's inception in 2014, Jeff has been a highly regarded member of the leadership team and this promotion is a reflection of his significant contributions to the company's growth, including Voyager's successful initial public offering in November 2015."

Mr. Goater has more than 15 years of business development and financial experience in the biotech industry. He has served in several executive roles since Voyager's launch in 2014, including senior vice president of finance and business development and vice president of business development. Prior to Voyager, Mr. Goater spent nearly a decade on Wall Street, most recently as a managing director at Evercore Partners, focused on strategic advisory in the life sciences sector. While at Evercore, he advised on more than $100 billion in M&A and licensing transactions. Mr. Goater began his Wall Street career as an equity research analyst at Cowen and Company, covering the biopharmaceutical sector. Prior to Cowen, he worked in biotech business development and began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.